Sugi Predict

Sugi Predict / Compounds / SCHEMBL5509686

SCHEMBL5509686

SCHEMBL5509686

CC(C)(C)OC(=O)NCC(C)(C)C(N)=O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.46
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ CA1 P00915 7/20 0.38
▸ CA2 P00918 7/20 0.38
▸ CA12 O43570 7/20 0.38
▸ CA9 Q16790 5/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ CA7 P43166 2/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ CA14 Q9ULX7 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18765048 0.85 MAOA (0.45) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL21952156 0.84 TDP1 (0.46) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL4325750 0.82 MAOA (0.54) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL1444341 0.82 MEN1 (0.49) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL13743905 0.81 TDP1 (0.43) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL23985309 0.80 TDP1 (0.46) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL14684133 0.80 DGAT1 (0.47) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL1332098 0.80 DGAT1 (0.47) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL16295315 0.80 MEN1 (0.47) MAOAMAOBTDP1MEN1KMT2A
SCHEMBL8908479 0.79 TDP1 (0.48) MAOAMAOBTDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3364967-B1 FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2026-05-20 — — EP disclosed
EP-3365339-B1 NOVEL FERROPORTIN INHIBITORS VIFOR INT AG (CH) 2025-07-16 — — EP disclosed
US-20220363675-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2022-11-17 — — US disclosed
CN-114668761-A Novel ferroportin inhibitors 威佛（国际）股份公司 2022-06-28 — — CN disclosed
CN-108290878-B Novel ferroportin inhibitors 威佛（国际）股份公司 2022-04-26 — — CN disclosed
US-11066399-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-07-20 — — US disclosed
US-11066399-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-07-20 — — US disclosed
US-20210139472-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-13 — — US disclosed
US-20210139472-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-13 — — US disclosed
US-11001579-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2021-05-11 — — US disclosed
US-10364239-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2019-07-30 — — US disclosed
US-10364239-B2 Ferroportin inhibitors VIFOR (INTERNATIONAL) AG (CH) 2019-07-30 — — US disclosed
US-20180319783-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2018-11-08 — — US disclosed
US-20180297991-A1 Novel Ferroportin Inhibitors VIFOR (INTERNATIONAL) AG (CH) 2018-10-18 — — US disclosed
WO-2017068089-A2 NOVEL FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2017-04-27 — — WO disclosed
WO-2017068090-A1 NOVEL FERROPORTIN INHIBITORS VIFOR (INTERNATIONAL) AG (CH) 2017-04-27 — — WO disclosed
US-20080293701-A1 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2008-11-27 — — US disclosed
US-20080293701-A1 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors VITAE PHARMACEUTICALS, INC. 2008-11-27 — — US disclosed
EP-1828147-A1 QUINOXALINES AS B-RAF INHIBITORS AstraZeneca AB (SE) 2007-09-05 — — EP disclosed
WO-2006040568-A1 QUINOXALINES AS B RAF INHIBITORS ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139472-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 MAOA 1505/4885MAOB 1123/4885TDP1 4674/4885
US-11066399-B2 Ferroportin inhibitors HAMP, SLC40A1, FTH1 MAOA 1307/4885MAOB 1051/4885TDP1 4745/4885
US-20180297991-A1 Novel Ferroportin Inhibitors SLC40A1, HAMP, TFRC MAOA 2047/4885MAOB 1515/4885TDP1 4231/4885
US-11001579-B2 Ferroportin inhibitors HAMP, SLC40A1, FTH1 MAOA 1307/4885MAOB 1051/4885TDP1 4745/4885
US-10364239-B2 Ferroportin inhibitors HAMP, SLC40A1, HMOX1 MAOA 648/4885MAOB 584/4885TDP1 4711/4885
US-20180319783-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, FTH1 MAOA 914/4885MAOB 820/4885TDP1 4669/4885
US-20080293701-A1 1-Acylamino-2-Hydroxy-3-Amino- -Arylalkanes as Renin Inhibitors REN, AGTR1, AGTR2 MAOA 533/4885MAOB 863/4885TDP1 3837/4885
US-20220363675-A1 Novel Ferroportin Inhibitors HAMP, SLC40A1, HMOX1 MAOA 1505/4885MAOB 1123/4885TDP1 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.